Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neurofibromatosis 2 × 1 year × Clear all

Phase

Phase 2 3 Phase NA 2 Phase 1/2 2 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 31 Carcinoma, Non-Small-Cell Lung 24 Neoplasm Metastasis 18 Breast Neoplasms 17 Prostatic Neoplasms 16 Colorectal Neoplasms 15 Carcinoma, Hepatocellular 12 Stomach Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 11 Lung Neoplasms 10 Recurrence 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Ovarian Neoplasms 9 Leukemia, Myeloid, Acute 9 Pancreatic Neoplasms 8 Myasthenia Gravis 8 Melanoma 8 Leukemia 7 Urinary Bladder Neoplasms 6 Rectal Neoplasms 6 Lymphoma 6 Hematologic Neoplasms 6 Glioblastoma 6 Fatigue 6 Endometrial Neoplasms 6 Cholangiocarcinoma 6 Multiple Myeloma 5 Mouth Neoplasms 5 Lymphoma, Large B-Cell, Diffuse 5 Laryngeal Neoplasms 5

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡